<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The nuclear factor kappa B (NFκB) pathway is essential for many human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutics such as <z:chebi fb="0" ids="52717">bortezomib</z:chebi> (<z:chebi fb="0" ids="52717">Velcade</z:chebi>™) that interfere with NFκB signaling are of great clinical interest </plain></SENT>
<SENT sid="2" pm="."><plain>NFκB signaling, however, is multifaceted and variable among tissues, developmental and disease entities </plain></SENT>
<SENT sid="3" pm="."><plain>Hence, targeted biomarkers of NFκB pathways are of prime importance for clinical research </plain></SENT>
<SENT sid="4" pm="."><plain>We developed a novel real-time qPCR-based NFκB array </plain></SENT>
<SENT sid="5" pm="."><plain>Only mechanistically validated NFκB targets were included </plain></SENT>
<SENT sid="6" pm="."><plain>We then used random-forest classification to define individual genes and gene combinations within the NFκB pathways that define <z:mp ids='MP_0001799'>viral</z:mp> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subclasses as well as Kaposi <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (KS) </plain></SENT>
<SENT sid="7" pm="."><plain>Few NFκB targets emerged that were universally present in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types tested, underscoring the need for additional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-type specific biomarker discovery </plain></SENT>
<SENT sid="8" pm="."><plain>(i) We uncovered tissue of origin-specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers, specifically CD69, CSF-1 and complement factor B (C1QBP) for primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PEL); IL1-beta, cyclinD3 and CD48 for KS </plain></SENT>
<SENT sid="9" pm="."><plain>We found that IL12, jun-B, msx-1 and thrombospondin 2 were associated with EBV co-<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in PEL </plain></SENT>
<SENT sid="10" pm="."><plain>(ii) We defined the NFκB signature of Epstein-Barr virus (EBV) positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-associated Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="11" pm="."><plain>This signature identified CCR5 as the key marker </plain></SENT>
<SENT sid="12" pm="."><plain>(iii) This signature differed from EBV negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> consistent with the idea that EBV not only activates NFκB activity but that this virus also reprograms NFκB signaling toward different targets </plain></SENT>
</text></document>